Roche fined for hindering entry of generic cancer drugs
Romania’s Competition Council has fined F. Hoffmann-La Roche’s local subsidiary €12.8 million for abusing its dominance in multiple cancer treatment markets, but the drugmaker has accused the enforcer of acting in bad faith and ignoring evidence of its innocence.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10